about
Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapyA novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiencesContributions to early HIV diagnosis among patients linked to care vary by testing venueComparison of emergency department HIV testing data with visit or patient as the unit of analysisEhrlichiosis presenting as a life-threatening illness with features of the toxic shock syndrome.Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087Risk, reasons for refusal, and impact of counseling on consent among ED patients declining HIV screening.Physician specialization and antiretroviral therapy for HIV.Specialty training and specialization among physicians who treat HIV/AIDS in the United States.Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.An immunocompetent patient with primary Scedosporium apiospermum vertebral osteomyelitis.Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem.Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexityHIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.Comparison of missed opportunities for earlier HIV diagnosis in 3 geographically proximate emergency departments.Preliminary program evaluation of emergency department HIV prevention counseling.Effect of an emergency department HIV testing program on the proportion of emergency department patients who have been tested.Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.Engagement of the CD4 receptor affects the redistribution of Lck to the immunological synapse in primary T cells: implications for T-cell activation during human immunodeficiency virus type 1 infection.Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.Does antiretroviral therapy increase or decrease the risk of cardiovascular disease?Fenofibrate in the treatment of dyslipidemia associated with HIV infection.Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis.Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295.Entrustment and mapping of observable practice activities for resident assessment.High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infectionPharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
P50
Q28741958-9FB111CD-BBCA-461A-A57C-31DE2AEBFE00Q33302710-69A0ABF9-D2BB-444E-8063-FFA8AA2F24A8Q33346660-4980D8D2-FE0D-4F41-8187-24A18287A13DQ33427350-00D96386-B756-493F-909D-8A46380496ECQ33492910-5AB9B052-A989-4FEE-9045-0B4A4FA5EBBFQ34099851-82B0BDD9-280B-4C16-B473-0D0AB8E743C5Q34400463-D41875AE-4E06-4E94-B0EA-526EFB66B940Q34741264-75C3788E-54C7-4248-84D5-70BE87943F8CQ34742801-426D4235-7C7A-4FA9-A5FA-AE3F393C46FAQ34796153-FA26A9F1-C9B7-4A47-9F2C-6C986B246921Q34978013-86CC5145-EE5E-46CB-8C39-A6B9C04E479EQ34983265-0D39B13B-C580-43C7-9DAE-68786A809321Q35546757-E66ABA25-1862-471C-8084-BD5C72379C57Q36030485-92C8CF23-BF61-426C-BFC4-67A96988726CQ36043719-870B3B2A-A09F-4F92-9AD7-A869AD2F1738Q36087108-0E152326-56E5-4071-8C0C-02BD4477B7F0Q36116238-31FC2F95-D394-458A-94F1-2F2384B0A84FQ36268919-ED7AE1E3-EFF7-4C11-9F84-CA6A3D46CE9CQ36377132-5622B9E0-C6A9-4022-BB62-9CF06389FFD0Q36528535-B8BC4EBF-6B41-46BF-9AB4-844DC26F35DAQ36555731-63809B7E-13FB-4B99-88DE-0F6BE696BCC1Q36783211-BDC913B0-7E74-4E24-B647-71760D3A19CBQ36868170-6B6F43AA-35A2-4A5C-A358-65572D488F4EQ36948159-4107AD55-1F33-4BDA-B7E0-E65FADACB451Q36948163-D647578B-004A-4EE8-A2DB-C6C22A8A0809Q36948190-742A6755-FFC7-4C06-AA55-6A6D9F91AF5EQ37016796-4DF449AC-E2AD-4B55-A7D9-8183DC0A63E7Q37051575-B3400F35-8E86-410B-AC86-03C72E42C2F9Q37086312-3D605565-EB32-4688-81A1-154563599663Q37458941-0F897658-4622-4D89-A5B2-A6AF26178AE7Q37738719-598F82BC-90A3-4F05-8708-20E1251C8784Q37770249-12E9D6C8-C674-4B76-BFE6-907424ECFABBQ38959758-8D729FBE-6ECD-456B-8052-B3713F1B703FQ39098346-53907D23-C42C-47C6-95FD-F87C455B1154Q39696831-A1A2FADC-D68D-4D18-A50F-7A71A37CC87CQ41736571-F5606F22-A0C2-40D0-AF5D-ECAC9B90ADD1Q41739500-3B38C5BD-D348-47B2-99B6-6E08C3E8159CQ41890513-7F99A7BE-F182-401E-8F0C-E94D39FE6F80Q42322488-F49DB5EC-030D-4542-8D5C-183E73D3FBACQ42671235-A6687455-7588-4808-866F-24F6D8562751
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carl Fichtenbaum
@ast
Carl Fichtenbaum
@en
Carl Fichtenbaum
@es
Carl Fichtenbaum
@nl
Carl Fichtenbaum
@sl
type
label
Carl Fichtenbaum
@ast
Carl Fichtenbaum
@en
Carl Fichtenbaum
@es
Carl Fichtenbaum
@nl
Carl Fichtenbaum
@sl
prefLabel
Carl Fichtenbaum
@ast
Carl Fichtenbaum
@en
Carl Fichtenbaum
@es
Carl Fichtenbaum
@nl
Carl Fichtenbaum
@sl
P106
P1153
7003851566
P21
P31
P496
0000-0002-6778-7253